Obese patients treated with thiopurines and anti-TNF could have worse outcomes compared to non-obese patients, due to subtherapeutic dosing: a retrospective study among 1494 IBD patients (634 UC, 860 CD) found a lower dosing per kilogram of AZA, 6-MP, methotrexate and anti-TNF in the obese subgroup (p < 0.0001) [104]. The gene discussed is TNF; the disease is inflammatory bowel disease.